CIMCURE
CimCure focuses on design and development of a novel class of active cancer immunotherapies.
CIMCURE
Industry:
Health Care Medical
Address:
Amsterdam, Noord-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.cimcure.com
Status:
Active
Contact:
+31 646 336 338
Total Funding:
5 M EUR
Investors List
Tom Würdinger
Tom Würdinger investment in Seed Round - CimCure
Official Site Inspections
http://www.cimcure.com Semrush global rank: 5.4 M Semrush visits lastest month: 1.56 K
- Host name: 37-97-131-246.colo.transip.net
- IP address: 37.97.131.246
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "CimCure"
CimCure – Cancer Immunotherapies
CimCure is an international biotech company that develops cancer vaccines which directly target and destroy the tumour’s network of blood vessels so that the cancer stops growing and eventually disappears. Through its proprietary …See details»
CimCure - Crunchbase Company Profile & Funding
Organization. CimCure . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... CimCure develops …See details»
CimCure 2025 Company Profile: Valuation, Funding & Investors
CimCure General Information Description. Developer of cancer immunotherapy designed for the treatment of solid tumors. The company has developed cancer vaccines through its proprietary …See details»
CimCure - Amsterdam, Netherlands
CimCure is a 2016 spin-off from Amsterdam UMC. CimCure focuses on the design and development of a novel class of active cancer immunotherapies. The company develops …See details»
Technology – CimCure
CimCure developed iBoost, a technology that makes use of an engineered bacterial designer protein. Mail: info@cimcure.com Phone: 0031 646 336 338. Mail: info@cimcure.com. Phone: …See details»
CimCure - Products, Competitors, Financials, Employees, …
CimCure is a biotech company focused on developing cancer immunotherapies. The company specializes in creating vaccines that target and destroy the tumor's blood vessel network, …See details»
CimCure - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Jun 7, 2022: Seed Round - …See details»
CimCure - Contacts, Employees, Board Members, Advisors & Alumni
CimCure focuses on design and development of a novel class of active cancer immunotherapies.See details»
CimCure - Medtech Alert
CimCure is a new generation company founded by its CSO in 2015, as a spin-off company of Amsterdam UMC. CimCure focuses on design and development of a novel class of active …See details»
Cancer vaccine biotech CimCure raises €5M
Jun 7, 2022 CimCure’s approach directly targets the tumor blood vessels, which reduces tumor growth directly and does not induce resistance. Earlier this year, CimCure received a €2.2M ($2.4M) award from the EU for a Eurostars project, …See details»
Roadmap – CimCure
Roadmap The Clinical phase will start in Q1 2025. CimCure’s partner, the Dutch vaccine contract development and manufacturing organisation (CDMO) Intravacc, is currently producing the …See details»
Amsterdam-based cancer vaccine biotech startup CimCure raises …
Jun 8, 2022 CimCure focuses on the design and development of a novel class of active cancer immunotherapies.See details»
CimCure - Crunchbase
CimCure focuses on design and development of a novel class of active cancer immunotherapies. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. …See details»
HealthTech: Dutch Intravacc to in-license CimCure’s iBoost …
Bilthoven, The Netherlands based Intravacc, a worldwide leading translational research and development vaccine organization with an extensive track record in developing viral and …See details»
Intravacc to In-license CimCure's iBoost Technology, Expanding its ...
Jul 1, 2020 CimCure/Amsterdam UMC received a 1.3 million euro grant from Health Holland, an investment organization of the Ministry of Economic Affairs. In the collaboration, CimCure will …See details»
Legacy - CimCure
CimCure’s research is directly aiming for that11,12. The large number of advantages of a vaccination approach over the use of small molecules or monoclonal antibodies underpins the …See details»
Cancer vaccine biotech CimCure raises € 5 million in seed round ...
Jun 7, 2022 IXA is a network, servicedesk and liaison organization for Amsterdam UMC, offering researchers the expertise of grant advisers, business developers and legal experts to help …See details»
Amsterdam-based biotech startup CimCure raises € 5m seed …
Jun 17, 2022 CimCure, a biotech spin-off of Amsterdam UMC, focusing on the development of a novel vaccine-based cancer immunotherapy through its Immune-Boost (iBoost) technology, …See details»
News - CimCure
CimCure secures € 3.9 million Innovation Credit Amsterdam, October 2023. Amsterdam – October, 2023. The Netherlands Enterprise Agency (RVO) has awarded CimCure with an …See details»